HLS Therapeutics (TSE:HLS) Rating Increased to Strong-Buy at Raymond James Financial

Raymond James Financial upgraded shares of HLS Therapeutics (TSE:HLS) from an outperform rating to a strong-buy rating in a research note issued to investors on Friday,BayStreet.CA reports. They currently have C$8.00 price target on the stock, up from their previous price target of C$7.00.

Separately, Canaccord Genuity Group upgraded HLS Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the stock. According to data from MarketBeat, HLS Therapeutics presently has a consensus rating of “Strong Buy” and a consensus target price of C$8.00.

HLS Therapeutics Price Performance

HLS Therapeutics stock opened at C$3.90 on Friday. HLS Therapeutics has a 52 week low of C$3.77 and a 52 week high of C$5.77. The firm has a market cap of C$121.97 million, a P/E ratio of -12.19 and a beta of -0.18. The company has a debt-to-equity ratio of 75.86, a quick ratio of 1.01 and a current ratio of 1.05. The business’s fifty day moving average is C$4.22 and its two-hundred day moving average is C$4.41.

HLS Therapeutics (TSE:HLS) last issued its earnings results on Wednesday, August 12th. The company reported C($0.03) earnings per share (EPS) for the quarter. The business had revenue of C$14.67 million during the quarter. HLS Therapeutics had a negative net margin of 15.26% and a negative return on equity of 14.39%. During the same quarter in the previous year, the business earned ($0.09) earnings per share. Equities research analysts forecast that HLS Therapeutics will post -0.12 earnings per share for the current fiscal year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.